Bioheart, Inc. (OTC Bulletin Board: BHRT) is one of the Emerging Biotech Presenters at the International Academy of Cardiology, 16th World Congress on Heart Disease, Annual Scientific Sessions July 23rd-26th in Vancouver at the Hyatt Regency Vancouver. Howard J. Leonhardt, Bioheart's Founder and Chief Technology Officer, will be presenting on Myoblast Transplantation for Heart Repair, a Review of the State of Field. His presentation will take place on Monday, July 25th, at 3:30 pm in Hall D Ballroom of the Hyatt Regency.

About Bioheart, Inc.

Bioheart is focused on completing its Phase II/III MARVEL study for MyoCell in treating advanced heart failure. The product candidate has been in clinical trials since May of 2001. The company believes, after 10 years of clinical trials that followed pre-clinical studies dating to 1988, that it may be on the final leg towards qualifying to apply for a biologics license approval FDA panel review. Approximately 130 patients more are needed to be completed in the randomized, double blinded, placebo controlled MARVEL Phase II/III Part II study. In the MARVEL Phase II/III Part I study the performance of MyoCell was nearly 500% above its primary end point goal of 16 meters improvement in exercise capacity testing. Bioheart MyoCell patients came in at 91.7 meters improvement while placebo injected patients had a 4 meter decline. Both groups were also on HFSA recommended optional CHF drugs. This small study MARVEL Phase II/III Part I data correlated well with the data gathered on nearly 300 patients in various myoblast transplantation to treat heart failure studies since 2000 and pre-clinical studies by Bioheart Scientific Advisory Board Members since 1988. This led to design and launch of the larger scale MARVEL Phase II/III Part II study.

MyoCell is a clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

Source: Bioheart, Inc